Elizabeth Haase, MD, former chair of the American Psychiatric Association's Committee on Climate Change, shared her advice ...

Zhdanava M et al. Esketamine Nasal Spray for Major Depressive Disorder With Acute Suicidal Ideation or Behavior: Description of Treatment Access, Utilization, and Claims-Based Outcomes in the ...

Psychedelic supervisors could help guide the experiences of people treated for depression with esketamine, which may come with a "trip." ...

Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

Ketamine or more specifically, its cousin — esketamine — has started to change the landscape of depression, especially where it borders on suicide. Ketamine may help severely depressed, study ...

President Trump pressed the VA to buy the new depression treatment esketamine, touting its results as “incredible.” As of mid-December, just 15 veterans have been treated.

Esketamine is for patients with "treatment-resistant depression," a major depressive disorder that at least two alternative antidepressant treatments failed to adequately address.

A nasal spray version of esketamine was more effective for depression that is resistant to treatment than a more commonly used drug, research published Wednesday in The New England Journal of ...

Last week, the FDA announced that it had officially approved Spravato, a brand-name nasal spray containing esketamine, a chemical cousin of ketamine, to treat depression.The drug was hailed by ...

BARCELONA — Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca), an atypical antipsychotic, for treatment-resistant depression (TRD ...

Janssen announced new findings from a Phase 2 study evaluating esketamine nasal spray in patients with major depressive disorder who were at imminent risk for suicide. The findings were published ...

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.